Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DFFN

Diffusion Pharmaceuticals (DFFN) Stock Price, News & Analysis

Diffusion Pharmaceuticals logo

About Diffusion Pharmaceuticals Stock (NASDAQ:DFFN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$4.38
$6.60
52-Week Range
N/A
Volume
351,000 shs
Average Volume
10,937 shs
Market Capitalization
$8.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive DFFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DFFN Stock News Headlines

Diffusion Pharmaceuticals Inc.
HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
See More Headlines

DFFN Stock Analysis - Frequently Asked Questions

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($9.00) earnings per share for the quarter, missing analysts' consensus estimates of ($3.00) by $6.00.

Shares of Diffusion Pharmaceuticals reverse split before market open on Thursday, August 17th 2023.The 1-1.5 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 67 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Diffusion Pharmaceuticals investors own include Tonix Pharmaceuticals (TNXP), Onconova Therapeutics (ONTX), OPKO Health (OPK), T2 Biosystems (TTOO), NightHawk Biosciences (NHWK), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
11/10/2021
Today
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DFFN
CIK
1053691
Employees
13
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.59 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-69.96%
Return on Assets
-62.98%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.71
Quick Ratio
10.71

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.97 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
2,040,000
Free Float
2,003,000
Market Cap
$8.98 million
Optionable
Not Optionable
Beta
1.78

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:DFFN) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners